Hydrochloric Acid

Hydrochloric Acid

SCHEMBL465147

Cl.PC(c1ccccc1)(c1ccccc1)c1ccccc1-c1ccccc1

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 known ✓ P27487 1/20 0.33
HDAC4 known ✓ P56524 1/20 0.32
HDAC2 known ✓ Q92769 1/20 0.32
HDAC8 known ✓ Q9BY41 1/20 0.32
HDAC6 known ✓ Q9UBN7 1/20 0.32
ALDH1A1 P00352 6/20 0.37
HSD17B10 Q99714 2/20 0.37
MAPK1 P28482 2/20 0.37
HPGD P15428 1/20 0.37
BCL2L1 Q07817 1/20 0.37
CYP2A6 P11509 1/20 0.37
KIF11 P52732 1/20 0.35
CYP2C9 P11712 1/20 0.35
BACE1 P56817 1/20 0.33
TP53 P04637 1/20 0.32
RAB9A P51151 1/20 0.32
KCNN4 O15554 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
BCAT2 O15382 1/20 0.31
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28151763 0.98 ALDH1A1 (0.35) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
SCHEMBL411476 0.98 ALDH1A1 (0.38) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Iodide SCHEMBL3443160 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
SCHEMBL2571569 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Water SCHEMBL10839715 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Bromide SCHEMBL659623 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Phosphine SCHEMBL28051041 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
SCHEMBL28235794 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Ammonia Solution, Strong SCHEMBL28011607 0.96 ALDH1A1 (0.37) ALDH1A1HSD17B10MAPK1HPGDBCL2L1
Iodide SCHEMBL28849490 0.94 ALDH1A1 (0.35) ALDH1A1HSD17B10MAPK1HPGDBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 909 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037814-A PP adhesive tape suitable for polymer soft package battery and preparation method thereof 佛山市远创新航新能源材料技术有限公司 2026-05-15 CN claimed
CN-115806569-A High-temperature-resistant quaternary phosphonium sulfonate organic antibacterial flame-retardant monomer for polyester polymerization, and preparation method and application thereof 浙江恒逸石化研究院有限公司 2023-03-17 CN claimed
EP-1347012-B2 Curable Fluoroelastomers SOLVAY SPECIALTY POLYMERS IT (IT) 2020-04-29 EP claimed
EP-3212682-B1 VULCANISABLE COMPOSITIONS COMPRISING ETHYLENE-VINYLACETATE-COPOLYMERS CONTAINING EPOXY GROUPS ARLANXEO DEUTSCHLAND GMBH (DE) 2019-01-09 EP claimed
US-20170335037-A1 VULCANIZABLE COMPOSITIONS CONTAINING EPOXY GROUP-CONTAINING ETHYLENE-VINYL ACETATE COPOLYMERS ARLANXEO DEUTSCHLAND GMBH (DE) 2017-11-23 US claimed
US-9522915-B2 Method for preparing an important intermediate of linagliptin 2Y-CHEM, LTD. (CN) 2016-12-20 US claimed
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN 2Y-CHEM, LTD. (CN) 2015-10-01 US claimed
US-9000058-B2 Process for devulcanizing vulcanized fluoroelastomers, fluoroelastomers thereof and their use DOTT. VIOLA & PARTNERS CHEMICAL RESEARCH S.R.L. (IT) 2015-04-07 US claimed
US-20140378562-A1 Process for devulcanizing vulcanized fluoroelastomers, fluoroelastomers thereof and their use DOTT. VIOLA & PARTNERS CHEMICAL RESEARCH S.R.L. (IT) 2014-12-25 US claimed
WO-2013132523-A1 PROCESS FOR DEVULCANIZING VULCANIZED FLUOROELASTOMERS, FLUOROELASTOMERS THEREOF AND THEIR USE DOTT. VIOLA & PARTNERS CHEMICAL RESEARCH S.R.L. (IT) 2013-09-12 WO claimed
WO-1997044376-A1 METHOD OF CATALYST DEACTIVATION IN CONTINUOUS POLYETHYLENE TEREPHTHALATE PRODUCTION WELLMAN, INC. (US) 1997-11-27 WO claimed
US-5658671-A ARTICLE COATED WITH COMPOSITION COMPRISING FLUOROELASTOMER, QUATERNARY AMMONIUM OR PHOSPHONIUM ACCELERATOR, POLYOL, ACID ACCEPTOR, OIL-SOLUBLE CHELATING AGENT, ORGANIC SOLVENT MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-08-19 US claimed
WO-1997000906-A1 IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS DYNEON LLC (US) 1997-01-09 WO claimed
US-5451625-A FOR USE IN THE PREPARATION OF AUTOMOTIVE GASKETS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-09-19 US claimed
US-5371143-A Polymer blend composition of fluorinated elastomers, thermoplastic polymers and thermoplastics elastomers MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-12-06 US claimed
US-5319025-A Curing fluorocarbon elastomers MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-06-07 US claimed
EP-0574319-A1 Fluoroelastomer coating composition MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-12-15 EP claimed
US-5008345-A Two-Part Curing System Containing A Metallic Acid Salt And An Ammonium Or Phosphonium Quaternary Salt ZEON CHEMICAL USA, INC. (US) 1991-04-16 US claimed
US-4931509-A EPOXY-CONTAINING MONOMER; EXCELLENT VULCANIZING WITH UREAS, QUATERNARY AMMONIUM AND PHOSPHONIUM SALTS AND POLYCARBOXYLIC ACIDS OR ANHYDRIDES NIPPON ZEON CO., LTD. (JP) 1990-06-05 US claimed
EP-0309794-A2 No-post-cure method of curing polyacrylate polymers Zeon Chemicals USA, Inc. (US) 1989-04-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN DPP4, DPP9, DPP3 DPP4 1/4885HDAC4 1177/4885HDAC2 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.